_full-di-balik-layar-bersama-elis-sinden-ki-eko-p-preview-1.jpg "FULL DI BALIK LAYAR BERSAMA ELIS - SINDEN KI EKO P. from sinden elis Video Screenshot Preview 1")
Gallery_full-di-balik-layar-bersama-elis-sinden-ki-eko-p-preview-3.jpg "FULL DI BALIK LAYAR BERSAMA ELIS - SINDEN KI EKO P. from sinden elis Video Screenshot Preview 3")
Gallery_full-di-balik-layar-bersama-elis-sinden-ki-eko-p-preview-hqdefault.jpg "FULL DI BALIK LAYAR BERSAMA ELIS - SINDEN KI EKO P. from sinden elis Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 11 minutes 25 seconds
👁 View: 69.8K times
Play Audio:👁 View: 69.8K times
Description:
WAYANG JAWA
WAYANG JAWA
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.webp "New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .<br/>NBC reports that patients taking <br/>Novo Nordisk's obesity treatment maintain <br/>an average of 10% weight loss over four years.<br/>The news potentially boosts the <br/>drugmaker's push for Wegovy to be <br/>covered by insurers and governments. .<br/>The company submitted long-term <br/>findings at the European Congress <br/>on Obesity in Venice, Italy. .<br/>This is the longest study <br/>we’ve conducted so far of <br/>semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.<br/>We see that once the majority <br/>of the weight loss is accrued, <br/>you don’t go back and start <br/>to increase in weight<br/>if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.<br/>According to another analysis published by <br/>the drugmaker, approximately 17% of trial participants stopped using the treatment <br/>due to side effects like nausea. .<br/>The costly treatment ranges from $200 <br/>to nearly $2,000 per month in the ten <br/>countries where the drug is available.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>Rival Eli Lilly launched its drug <br/>Zepbound in the United States <br/>in December of 2023. .<br/>Neither drugmaker has managed <br/>to produce enough of the <br/>treatment to meet surging demand")
_percil-cs-lucu-poll-mbak-elis-gak-kuwat-ngobahne-awak-dijamin-ngakak-lurd-wk-wk.webp "WAYANG JAWA")
⏲ 8 minutes 39 seconds 👁 17K
_eli-crane-to-experts-has-the-fbi-39dropped-the-ball39-on-anomalous-health-incidents-investigation.webp "During a House Homeland Security Committee hearing on Wednesday, Rep. Eli Crane (R-AZ) spoke about the FBI's investigation into anomalous health incidents.<br/><br/>Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:<br/><br/>https://account.forbes.com/membership/?utm_source=youtube&utm_medium=display&utm_campaign=growth_non-sub_paid_subscribe_ytdescript<br/><br/><br/>Stay Connected<br/>Forbes on Facebook: http://fb.com/forbes<br/>Forbes Video on Twitter: http://www.twitter.com/forbes<br/>Forbes Video on Instagram: http://instagram.com/forbes<br/>More From Forbes:http://forbes.com")
⏲ 6:26 👁 4.8M
_edan-brotoseno-elis-natalis.webp "Budaya Jawa")
_kangen-peye-mbak-elis-berpenampilan-beda.webp "Riyadi TV")
_time100-health-panel-talks-medical-gaslighting-and-investing-in-womens-health.webp "Actress and healthcare advocate Halle Berry; geneticist Marlena Fejzo; and Daniel Skovronsky, chief scientific officer at pharmaceutical giant Eli Lilly, spoke about the importance of investing in women’s health at a TIME100 Health panel in New York on Monday.")
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.jpg)
_percil-cs-lucu-poll-mbak-elis-gak-kuwat-ngobahne-awak-dijamin-ngakak-lurd-wk-wk.jpg)
_eli-crane-to-experts-has-the-fbi-39dropped-the-ball39-on-anomalous-health-incidents-investigation.jpg)
_edan-brotoseno-elis-natalis.jpg)
_kangen-peye-mbak-elis-berpenampilan-beda.jpg)
_time100-health-panel-talks-medical-gaslighting-and-investing-in-womens-health.jpg)
![[+]](/images/menu.gif){kind=small}